Matched sibling donor hematopoietic stem cell transplantation for thalassemia

Current Opinion in Hematology

Volumn 23, Issue 6, 2016, Pages 508-514

  Issaragrisil, Surapol ^a,b   Kunacheewa, Chutima ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Department of Obstetrics and Gynecology   (Thailand)

Author keywords

class 3; matched sibling donor bone marrow transplantation; novel conditioning; thalassemia

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HYDROXYUREA; THIOTEPA; THYMOCYTE ANTIBODY; HLA ANTIGEN;

BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL OUTCOME; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; MATCHED SIBLING DONOR; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; THALASSEMIA; THALASSEMIA MAJOR; AGE; ALLOTRANSPLANTATION; CLINICAL STUDY; COMPLICATION; FEMALE; GENETICS; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; PROCEDURES; SIBLING; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

AGE FACTORS; BONE MARROW TRANSPLANTATION; CLINICAL STUDIES AS TOPIC; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IRON OVERLOAD; MALE; SIBLINGS; THALASSEMIA; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84981714779     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000286     Document Type: Review

References (32)

1. Weatherall DJ, Williams TN, Allen SJ, O'Donnell A. The population genetics and dynamics of the thalassemias. Hematol Oncol Clin North Am 2010; 24:1021-1031.
2. Wasi P. Haemoglobinopathies including thalassaemia. Part 1: Tropical Asia. Clin Haematol 1981; 10:707-729.
3. Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol 2000; 7:106-112.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193.
5. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up. Blood 2011; 118:884-893.
6. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet 1982; 2:227-229.
7. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322:417-421.
8. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329:840-844.
9. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation. Blood Rev 2002; 16:81-85.
10. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996; 87:2082-2088.
11. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel. Haematologica 2014; 99:811-820.
12. Mathews V, George B, Deotare U, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:889-894.
13. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood 2011; 117:1745-1750.
14. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104:1201-1203.
15. Gaziev J, Isgro A, Sodani P, et al. Optimal outcomes in young class 3 patients with thalassemia undergoing HLA-identical sibling bone marrow transplantation. Transplantation 2016; 100:925-932.
16. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk beta thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PloS One 2013; 8:e61637.
17. Anurathapan U, Pakakasama S, Rujkijyanont P, et al. Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: A safe approach to disease control. Biol Blood Marrow Transplant 2013; 19:1259-1262.
18. Anurathapan U, Pakakasama S, Mekjaruskul P, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. Biol Blood Marrow Transplant 2014; 20:2066-2071.
19. Lucarelli G, Clift RA, Galimberti M, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93:1164-1167.
20. Issaragrisil S, Visuthisakchai S, Suvatte V, et al. Transplantation of cord-blood stem cells into a patient with severe thalassemia. N Engl J Med 1995; 332:367-369.
21. Locatelli F, Rocha V, ReedW, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101:2137-2143.
22. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122:1072-1078.
23. Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: A report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant 2016; 51:536-541
24. Gaziev J, Sodani P, Polchi P, et al. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Ann N Y Acad Sci 2005; 1054:196-205.
25. Goussetis E, Peristeri I, Kitra V, et al. HLA-matched sibling stem cell transplantation in children with beta-thalassemia with anti-thymocyte globulin as part of the preparative regimen: The Greek experience. Bone Marrow Transplant 2012; 47:1061-1066.
26. Galambrun C, Pondarre C, Bertrand Y, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: Lessons and future directions. Biol Blood Marrow Transplant 2013; 19:62-68.
27. Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant 2016; 51:813-818.
28. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25:401-404.
29. Andreani M, Testi M, Battarra M, et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008; 6:143-149.
30. Andreani M, Testi M, Lucarelli G. Mixed chimerism in haemoglobinopathies: From risk of graft rejection to immune tolerance. Tissue Antigens 2014; 83:137-146.
31. Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Ann N Y Acad Sci 2016; 1368:115-121.
32. Gaziev D, Giardini C, Angelucci E, et al. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995; 80:300-304.